Compositions and procedures for the treatment of lupus nephritis
Patent Information
- Application Number
- DE602020064799
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-04-03
- Filing Date
- 2020-09-10
- Publication Date
- 2025-12-31
- Estimated Expiration
- 2040-09-10
AI Technical Summary
Current treatments for lupus nephritis, such as rituximab and ocrelizumab, have shown limited efficacy and are associated with serious adverse events, while obinutuzumab's potential in treating lupus nephritis remains unexplored in long-term therapy and outcomes.
A treatment regimen involving obinutuzumab administered in four doses at weeks 0, 2, 24, and 26, followed by additional doses every six months, combined with mycophenolate mofetil and glucocorticoids, to achieve sustained B-cell depletion and improved renal response in lupus nephritis patients.
The regimen results in significant B-cell depletion, leading to increased complete and partial renal responses with reduced serious adverse events, maintaining efficacy for at least 52 weeks post-treatment.